Trabectedin
- PDF / 169,499 Bytes
- 1 Pages / 595.245 x 841.846 pts (A4) Page_size
- 72 Downloads / 134 Views
1
S
Atrial flutter, and elevation on transaminase and creatine kinase: 3 case reports In a retrospective study involving 9 patients treated between 2017 and 2019, 3 patients [ages an sexes not stated] were described, of whom one patient developed grade 2 increase of transaminase, one patient developed atrial flutter, and the remaining one patient developed grade 3 increase of creatine kinase following treatment with continuous infusion of trabectedin 1.5 mg/m2 administered in 24 hours every 21 days for mesothelioma. The patient, who developed atrial flutter, had HR of 180 [duration of treatment to reactions onsets and outcomes not stated]. Author comment: "A grade 2 increase of transaminase was observed in 1 patient and a patient developed an atrial flutter with a heartrate of 180 during treatment." "There were not G3-4 hematological toxicities but a G3 increase of creatine kinase was observed in 1 patient." "Trabectedin in pre-treated mesothelioma patients is feasible with a moderate toxicity". Pasquini G, et al. P1.15-10 Trabectedin Has Limited Clinical Activity in Pretreated Patients with Pleural Mesothelioma. Journal of Thoracic Oncology 14 (Suppl.): S583-S584, No. 10, Oct 2019. Available from: URL: http://doi.org/10.1016/ 803432461 j.jtho.2019.08.1223 [abstract] - Italy
0114-9954/19/1778-0001/$14.95 Adis © 2019 Springer Nature Switzerland AG. All rights reserved
Reactions 9 Nov 2019 No. 1778
